Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Trial Profile

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions
  • Acronyms EASE LID 2
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2017 Interim (n=223) results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 08 Jun 2017 According to an Adamas Pharmaceuticals media release, results from this study were presented at the 21st International Congress of Parkinsons Disease and Movement Disorders.
    • 08 Jun 2017 Results published in an Adamas Pharmaceuticals, Inc. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top